Your browser doesn't support javascript.
Intranasal delivery of replicating mRNA encoding neutralizing antibody against SARS-CoV-2 infection in mice.
Li, Jia-Qi; Zhang, Zhe-Rui; Zhang, Hong-Qing; Zhang, Ya-Nan; Zeng, Xiang-Yue; Zhang, Qiu-Yan; Deng, Cheng-Lin; Li, Xiao-Dan; Zhang, Bo; Ye, Han-Qing.
  • Li JQ; Key Laboratory of Special Pathogens and Biosafety, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, China.
  • Zhang ZR; University of Chinese Academy of Sciences, 100049, Beijing, China.
  • Zhang HQ; Key Laboratory of Special Pathogens and Biosafety, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, China.
  • Zhang YN; University of Chinese Academy of Sciences, 100049, Beijing, China.
  • Zeng XY; Key Laboratory of Special Pathogens and Biosafety, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, China.
  • Zhang QY; University of Chinese Academy of Sciences, 100049, Beijing, China.
  • Deng CL; Key Laboratory of Special Pathogens and Biosafety, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, China.
  • Li XD; University of Chinese Academy of Sciences, 100049, Beijing, China.
  • Zhang B; Key Laboratory of Special Pathogens and Biosafety, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, China.
  • Ye HQ; University of Chinese Academy of Sciences, 100049, Beijing, China.
Signal Transduct Target Ther ; 6(1): 369, 2021 10 25.
Article in English | MEDLINE | ID: covidwho-1483125
ABSTRACT
The lung is the prophylaxis target against SARS-CoV-2 infection, and neutralizing antibodies are a leading class of biological products against various infectious viral pathogen. In this study, we develop a safe and cost-effective platform to express neutralizing antibody in the lung with replicating mRNA basing on alphavirus replicon particle (VRP) delivery system, to prevent SARS-CoV-2 infections. First, a modified VEEV replicon with two subgenomic (sg) promoters was engineered to translate the light and heavy chains of antibody simultaneously, for expression and assembly of neutralizing anti-SARS-CoV-2 antibody CB6. Second, the feasibility and protective efficacy of replicating mRNA against SARS-CoV-2 infection were demonstrated through both in vitro and in vivo assays. The lung target delivery with the help of VRP system resulted in efficiently block SARS-CoV-2 infection with reducing viral titer and less tissue damage in the lung of mice. Overall, our data suggests that expressing neutralizing antibodies in the lungs with the help of self-replicating mRNA could potentially be a promising prophylaxis approach against SARS-CoV-2 infection.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Replicon / Alphavirus / Antibodies, Neutralizing / SARS-CoV-2 / COVID-19 / Antibodies, Viral Limits: Animals Language: English Journal: Signal Transduct Target Ther Year: 2021 Document Type: Article Affiliation country: S41392-021-00783-1

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Replicon / Alphavirus / Antibodies, Neutralizing / SARS-CoV-2 / COVID-19 / Antibodies, Viral Limits: Animals Language: English Journal: Signal Transduct Target Ther Year: 2021 Document Type: Article Affiliation country: S41392-021-00783-1